Register Now - Beyond Recruitment: The Future of Patient Site Engagement in Oncology Clinical Trials

Yaning Wang, PhD

CEO, Createrna Science and Technology, former Director of FDA’s Division of Pharmacometrics

Articles by Yaning Wang, PhD

Understanding FDA’s Perspective on Precision Dosing

ByYaning Wang, PhD,Sirj Goswami, PhD

March 3rd 2022

Continued embrace of precision dosing will reduce costs and optimize clinical outcomes.

PK in Late Phase Trials

ByRajnikanth Madabushi,Jeffry Florian,Fang Li,Christoffer W. Tornoe,Christine Garnett,Hao Zhu,Yaning Wang, PhD,Nitin Mehrotra,Anshu Marathe,Jiang Liu,Venkatesh A. Bhattaram,Pravin R. Jadhav,Jogarao V. Gobburu,Joo-Yeon Lee,Kevin Krudys,Justin C. Earp

February 1st 2012

Applied Clinical Trials

Collecting PK data in late phase trials led to alleviating additional trials, drug approval, and better dosing.

Latest Updated Articles

PK in Late Phase Trials
February 1st 2012

Trending on Applied Clinical Trials Online

Comparing OpenAI and Mistral on Clinical Trial Matching

Embedding AI Across the Clinical Operating Model: Q&A with Rajneesh Patil, Syneos Health

From Complexity to Endpoint Meaningfulness: Addressing Key Neuroscience Trial Challenges with eCOA

From Signal to Action: Why Faster Trial Data Isn’t Producing Faster Decisions

ACT Brief: Community Research Financing Gaps, Neuroscience Endpoint Data, and Teva’s Biosimilar Deal